Ranibizumab

Generic Name
Ranibizumab
Brand Names
Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
Drug Type
Biotech
Chemical Formula
-
CAS Number
347396-82-1
Unique Ingredient Identifier
ZL1R02VT79
Background

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular (wet) age-related macular degeneration. The development of ranibizumab first began after bevacizumab, another anti-VEGF anticancer drug, was discovered to inhibit neovascularization and used in the off-label treatment of neovascular age-related macular degeneration for intravenous injection. In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use.

Ranibizumab was initially approved by the FDA in 2006 and by the European Commission (EC) in 2007. It is marketed under the brand names LUCENTIS and SUSVIMO. BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada. In August 2022, other biosimilars CIMERLI and RAIVISIO were approved by the FDA and EC, respectively.

Indication

Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.

Ranibizumab injection for for intravitreal use via ocular implant is used to treat Neovascular (wet) Age-related Macular Degeneration (AMD) in patients who have responded to at least two intravitreal injections of a VEGF inhibitor.

Associated Conditions
Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
Associated Therapies
-

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

First Posted Date
2014-11-26
Last Posted Date
2024-10-31
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
96
Registration Number
NCT02302079
Locations
🇺🇸

Site US10021, Phoenix, Arizona, United States

🇺🇸

Site US10004, Beverly Hills, California, United States

🇺🇸

Site US10030, McAllen, Texas, United States

and more 18 locations

Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients

First Posted Date
2014-11-20
Last Posted Date
2015-08-11
Lead Sponsor
East Florida Eye Institute
Target Recruit Count
80
Registration Number
NCT02296567
Locations
🇺🇸

East Florida Eye Institute, Stuart, Florida, United States

Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

First Posted Date
2014-11-17
Last Posted Date
2017-11-17
Lead Sponsor
Associated Retinal Consultants, Michigan
Target Recruit Count
13
Registration Number
NCT02291887
Locations
🇺🇸

Associated Retinal Consultants, Royal Oak, Michigan, United States

Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen

First Posted Date
2014-10-24
Last Posted Date
2020-12-04
Lead Sponsor
Anders Kvanta
Target Recruit Count
40
Registration Number
NCT02274259
Locations
🇸🇪

St Eriks Eye Hospital, Stockholm, Sweden

Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

First Posted Date
2014-10-07
Last Posted Date
2016-10-27
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT02258009
Locations
🇩🇪

Novartis Investigative Site, Chemnitz, Germany

Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD

First Posted Date
2014-08-18
Last Posted Date
2018-10-11
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
30
Registration Number
NCT02218177
Locations
🇨🇦

Toronto Western Hospital, Toronto, Ontario, Canada

Noctura400 Treatment for Diabetic Retinopathy (CANDLE)

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2014-08-04
Last Posted Date
2023-08-14
Lead Sponsor
PolyPhotonix Medical
Target Recruit Count
252
Registration Number
NCT02207712
Locations
🇬🇧

Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, Cambridgeshire, United Kingdom

🇬🇧

Colchester Hospital University NHS Foundation Trust, Colchester, Essex, United Kingdom

🇬🇧

Ashford & St Peters Hospitals NHS Foundation Trust, Chertsey, Surrey, United Kingdom

and more 15 locations

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

First Posted Date
2014-07-10
Last Posted Date
2015-07-14
Lead Sponsor
Allergan
Target Recruit Count
151
Registration Number
NCT02186119

A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration

First Posted Date
2014-07-04
Last Posted Date
2017-04-25
Lead Sponsor
Allergan
Target Recruit Count
25
Registration Number
NCT02181504
Locations
🇯🇵

Nihon University Hospital, Chiyoda-ku,Tokyo, Japan

🇯🇵

1 Fukushima Medical University, Fukushima-shi, Japan

🇯🇵

Kyushu University Hospital, Kita-ku, Fukuoka-shi Fukuoka, Japan

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath